Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581270 | 1.00 | POLB (0.43) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL1581269 | 1.00 | POLB (0.43) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL15524670 | 0.84 | POLB (0.41) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL15524669 | 0.84 | POLB (0.41) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL15063102 | 0.80 | GAA (0.45) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL15063103 | 0.80 | GAA (0.45) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL2564897 | 0.78 | GAA (0.36) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL10215923 | 0.78 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTNPSR1 | |
| SCHEMBL15524422 | 0.78 | GAA (0.36) | POLBSMN1; SMN2GAAALDH1A1MEN1 | |
| SCHEMBL30201901 | 0.77 | POLB (0.54) | POLBSMN1; SMN2GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-9617261-B2 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-04-11 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| WO-2014204263-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | THE ASAN FOUNDATION (KR) | 2014-12-24 | — | — | WO | disclosed |
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1673339-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108041-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS | MAP3K1, MAP3K5, MAP3K6 | POLB 693/4885SMN1; SMN2 3278/4885GAA 4115/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | POLB 1430/4885SMN1; SMN2 4003/4885GAA 3119/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | POLB 2502/4885SMN1; SMN2 1978/4885GAA 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.